Janssen's neuro division churns out Rapport, a new $100M biotech from Third Rock’s clinical data hunt
A new neuroscience biotech is in the works, and it’s already in the clinic with an epilepsy drug born out of Johnson & Johnson’s Janssen.
Coming out of the work of chief scientific officer and former Janssen neuro leader David Bredt, Rapport Therapeutics unveiled itself Tuesday with a Phase I study for drug-resistant epilepsy. The $100 million Series A financing should take RAP-219 to multiple mid-stage studies in various indications and shuttle two discovery-stage programs toward the clinic, Third Rock Ventures partner and Rapport director Reid Huber told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
